مقدمه:

 

دوزهای متفاوت از مورفین از طریق رسپتورهای اپیوئیدی کاپا و دلتا بر روی میوسیت های قلبی اثر میگذارند. هدف از این مطالعه بررسی اثرات اعتیاد به مورفین بر وسعت ضایعه انفارکتوس میوکارد ومیزان کراتین فسفوکیناز و لاکتات دهیدروژناز در موشهای صحرایی نر بوده است.

 

 

 

این آزمایش بر روی 30 موش صحرایی نر با میانگین وزنی 200 -250 گرم انجام گرفت. موش ها به سه گروه کنترل، گروه تجربی 1 ( مصرف مزمن مورفین+ انفارکتوس+40 میلی گرم برکیلوگرم مورفین) و گروه تجربی 2 (مصرف مزمن مورفین+ انفارکتوس+20 میلی گرم برکیلوگرم مورفین) تقسیم شدند.

 

جراحی به روش لیگاسیون به منظور القاء انفارکتوس در هر سه گروه صورت گرفت. سرانجام بعد از دو روز از همه موش ها نمونه خون برای تعیین میزان آنزیم های کراتین فسفوکیناز و لاکتات دهیدروژناز گرفته شد. در پایان دو روز، موش ها کشته شدند و بافت عضله قلبی جهت اندازه گیری وسعت ضایعه مورد بررسی قرار گرفت.

نتایج: یافته های این مطالعه نشان داد که تجویز مورفین حجم انفارکتوس و سطوح کراتین فسفوکیناز و لاکتات دهیدروژناز را درگروه های مورد مطالعه کاهش داد.

 

نتیجه گیری:

 

با توجه به یافته های این مطالعه چه بسا تجویز مورفین به افراد معتاد، به مقدار مصرف قبلیشان پیش از رخداد انفارکتوس میوکارد، باعث کاهش علائم سندرم ترک شده، کاهش وسعت ضایعه انفارکتوس میوکارد در این افراد را در پی داشته باشد.

 

.Justice, T., et al., World Drug Report, in https://www.unodc.org/unodc/en/data-and-

analysis/WDR-.html.

. 2011.

Trojniar, W. and I. Klejbor, Facilitatory effect of unilateral lesion of the ventral tegmental area on locomotor response to stimulation of the contralateral ventral tegmental area: involvement of GABAergic transmission. Brain research, 1999;. 842(2): p. 419-30.

Koneru, A., S. Satyanarayana, R., and S. izwan, Endogenous opioids: their physiological role and receptors. Global J Pharmacol, 2009. 3(3): p. 149-53.

Wise, R. and P.-P. Rompré, Brain dopamine and reward. Annual review of psychology, 1989. 40(1): p. 191-225.

Koob, G., P. Sanna, and F. Bloom, Neuroscience of addiction. Neuron, 1998. 21(3): p. 467-76.

Smart, D. and D. Lambert, The stimulatory effects of opioids and their possible role in the development of tolerance. Trends in pharmacological sciences, 1996 Jul. 17(7): p. 264-9.

Goodman, L., Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill New York, 1996.

Ida, M., Clinical Biochemistry and Hematology, in The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents. 2012. p. 57-116.

Wang, G.-Y., et al., κ-but not δ-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. American Journal of Physiology-Heart and Circulatory Physiology, 2001. 280(1): p. H384-H91.

Gao, E., et al., A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse.

Marghmaleki, V., et al., Effect of Physical Activity on Symptoms of Morphine Addiction in Rats, after and before of Lesion of the mPFC Area. Iranian journal of basic medical sciences, 2013. 16(10): p. 1091.

Ludwig, L., et al., Morphine enhances pharmacological preconditioning by isoflurane: Role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology, 2003. 98: p. 705-711.

Portoghese, P.S., M. Sultana, and A.E. Takemori, Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J Med Chem, 1990. 33(6): p. 1714-20.

Kato, R. and P. Foex, Fentanyl reduces infarction but not stunning via delta-opioid receptors and protein kinase C in rats. Br J Anaesth, 2000. 84(5): p. 608-14.

Zhang, Y., et al., Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors. Anesthesiology, 2005. 102(2): p. 371-8.

Bolling, S.F., et al., Opioids confer myocardial tolerance to ischemia: interaction of delta opioid agonists and antagonists. J Thorac Cardiovasc Surg, 2001. 122(3): p. 476-81.

Engelbrecht, A.M., et al., p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes. Basic Res Cardiol, 2004. 99(5): p. 338-50.

Fischer, P. and D. Hilfiker-Kleiner, Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol, 2007. 102(5): p. 393-411.

Mourouzis, I., et al., Morphine administration at reperfusion fails to improve postischaemic cardiac function but limits myocardial injury probably via heat-shock protein 27 phosphorylation. Eur J Anaesthesiol, 2009. 26(7): p. 572-81.

Gross, E.R., A.K. Hsu, and G. Gross, Opioid-induced cardioprotection occur via glycogen synthase kinase b inhibition during reperfusion in intact rat hearts. Circ Res, 2004. 94: p. 960-966.

Ramadan, R., et al., Myocardial ischemia during mental stress: role of coronary artery disease burden and vasomotion. J Am Heart Assoc, 2013. 2(5): p. e000321.

Schwartz, B.G., et al., When and why do heart attacks occur? Cardiovascular triggers and their potential role. Hosp Pract (1995), 2010. 38(3): p. 144-52.

Masoomi, M., et al., Abrupt opium discontinuation has no significant triggering effect on acute myocardial infarction. J Cardiovasc Med (Hagerstown), 2011. 12(4): p. 234-8.

Marmor, M., et al., Coronary artery disease and opioid use. Am J Cardiol, 2004. 93(10): p. 1295-7.

Hosseini, S.K., et al., Opium consumption and coronary atherosclerosis in diabetic patients: a propensity score-matched study. Planta Med, 2011. 77(17): p. 1870-5.

Hassanian-Moghaddam, H., S. Afzali, and A. Pooya, Withdrawal syndrome caused by naltrexone in opioid abusers. Hum Exp Toxicol, 2014. 33(6): p. 561-7.

Sabzghabaee, A.M., et al., Role of Benzodiazepines in the management of agitation due to inappropriate use of naltrexone. Iran J Nurs Midwifery Res, 2012. 17(5): p. 365-9.

Kotla, S.K. and C. Nathaniel, Recurrent stress-induced cardiomyopathy: a case report and review article. Case Rep Med, 2011. 2011: p. 160802.

Fuertes, G., M. Laorden, and M. Milanes, Noradrenergic and dopaminergic activity in the hypothalamic paraventric- ular nucleus after naloxone-induced morphine with- drawal. Neuroendocrinology, 2000. 71(1): p. 60-7.

Laorden, M., et al., Changes in catecholaminergic pathways innervat- ing paraventricular nucleus and pituitary-adrenal axis response during morphine dependence: implication of ®1-and ®2-adrenoceptors. Journal of Pharmacology and Experimental Therapeutics, 2000. 293(2): p. 578-84.

Bybee, K.A. and A. Prasad, Stress-related cardiomyopathy syndromes. Circulation, 2008. 118(4): p. 397-409.

Wittstein, I.S., Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? Cell Mol Neurobiol, 2012. 32(5): p. 847-57.

Sadeghian, S., et al., Opium consumption in men and diabetes mellitus in women are the most important risk factors of premature coronary artery disease in Iran. Int J Cardiol, 2010. 141(1): p. 116-8.

Asgary, S., et al., Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter? Lipids Health Dis, 2008. 7: p. 42.

Das, B., M.K. Daga, and S.K. Gupta, Lipid Pentad Index: A novel bioindex for evaluation of lipid risk factors for atherosclerosis in young adolescents and children of premature coronary artery disease patients in India. Clin Biochem, 2007. 40(1-2): p. 18-24.

Sadr Bafghi, S., et al., Is opium addiction a risk factor for acute myocardial infarction? Acta Medica Iranica, 2005. 43: p. 218-222.

Schultz, J.e.-J., et al., TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. Am J Physiol, 1998. 274(3 Pt 2): p. H909-14.

Somogyi, A.A., et al., Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol, 2008. 66(5): p. 640-7.

Toth, A.R. and T. Varga, Myocardium and striated muscle damage caused by licit or illicit drugs. Leg Med (Tokyo), 2009. 11 Suppl 1: p. S484-7.

(2006)., N.R., Data to the EMCDDA by the Reitox National Focal Point. 2007: p. 53-55.

Mohammad, A., et al., Effect of opium addiction on lipid profile and atherosclerosis formation in hypercholesterolemic rabbits. Experiment Toxicol Pathol, 2009. 61: p. 145-149.